title: Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.
abstract: During 2002-2010, a total of 30840 Escherichia coli clinical isolates from intra-abdominal infections were collected globally in the Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance programme. The incidence of extended-spectrum β-lactamase (ESBL)-producing isolates ranged from 9.2% in 2002 to 21.2% in 2010. The highest rates were observed in Asia (38.3%) and Latin America (22.9%) and the lowest rates in Africa (6.3%), North America (6%) and South Pacific (5.8%). Global susceptibility trends showed that there were only minor fluctuations in susceptibility to ertapenem and imipenem, with no significant decrease over time. Against ESBL-positive isolates, ertapenem susceptibility significantly increased during 2002-2010 globally. Moreover, susceptibility to ertapenem in the different geographical regions studied was also high, with only minor fluctuations generally observed. Notably, in Asia where the highest ESBL-positives rates (38.3%) were observed, susceptibility to ertapenem had actually significantly increased in this population during the 9-year study period. By contrast, susceptibility to amikacin, cephalosporins, fluoroquinolones and β-lactam/β-lactamase inhibitor combinations generally decreased over time. Further monitoring of the susceptibility to ertapenem and other antibiotics through SMART is warranted.
authors.affiliation: IHMA Europe Sàrl, 9A Route de la Corniche, 1066 Epalinges, Switzerland. shawser@ihmainc.com
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hawser
authors.forename: Robert E
authors.initials: RE
authors.lastname: Badal
authors.forename: Samuel K
authors.initials: SK
authors.lastname: Bouchillon
authors.forename: Daryl J
authors.initials: DJ
authors.lastname: Hoban
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Biedenbach
authors.forename: Rafael
authors.initials: R
authors.lastname: Cantón
authors.forename: David L
authors.initials: DL
authors.lastname: Paterson
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology*; D014943:Global Health; D006801:Humans; D059413:Intraabdominal Infections / Q000453:epidemiology / Q000382:microbiology*; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000378:metabolism; D047090:beta-Lactams / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D001618:beta-Lactamases; D000077727:Ertapenem